Literature DB >> 28619512

PART-1 functions as a competitive endogenous RNA for promoting tumor progression by sponging miR-143 in colorectal cancer.

Yongbo Hu1, Zhen Ma1, Yiming He1, Wei Liu1, Yu Su1, Zongbin Tang2.   

Abstract

LncRNAs were altered in several cancers and played a crucial role in various biological activities and progressions of different diseases, including proliferation, chemical resistance, and metastasis. In the present study, we revealed that prostrate androgen-regulated transcript-1 (PART-1) was highly expressed in colorectal cancer cells and tissues, and knockdown of PART-1 suppressed cell proliferation and metastasis, both in vitro and in vivo. In addition, PART-1 functioned as a ceRNA of DNMT3A, by sponging miR-143. Finally,PART-1 induced tumor progression by regulating DNMT3A.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; DNMT3A; Metastasis; PART-1; ceRNA; miR-143

Mesh:

Substances:

Year:  2017        PMID: 28619512     DOI: 10.1016/j.bbrc.2017.06.042

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

1.  Long non-coding RNA FAL1 functions as a ceRNA to antagonize the effect of miR-637 on the down-regulation of AKT1 in Hirschsprung's disease.

Authors:  Yang Li; Lingling Zhou; Changgui Lu; Qiyang Shen; Yang Su; Zhengke Zhi; Feng Wu; Hua Zhang; Zechao Wen; Guanglin Chen; Hongxing Li; Yankai Xia; Weibing Tang
Journal:  Cell Prolif       Date:  2018-07-30       Impact factor: 6.831

Review 2.  Long non‑coding RNA PART1: dual role in cancer.

Authors:  Rui Ran; Chao-Yang Gong; Zhi-Qiang Wang; Wen-Ming Zhou; Shun-Bai Zhang; Yong-Qiang Shi; Chun-Wei Ma; Hai-Hong Zhang
Journal:  Hum Cell       Date:  2022-07-21       Impact factor: 4.374

3.  Construction and analysis for differentially expressed long non-coding RNAs and MicroRNAs mediated competing endogenous RNA network in colon cancer.

Authors:  Fengxi Li; Qian Li; Xianghua Wu
Journal:  PLoS One       Date:  2018-02-08       Impact factor: 3.240

Review 4.  miRNA Clusters with Down-Regulated Expression in Human Colorectal Cancer and Their Regulation.

Authors:  Paulína Pidíkova; Richard Reis; Iveta Herichova
Journal:  Int J Mol Sci       Date:  2020-06-29       Impact factor: 5.923

5.  A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.

Authors:  Qian Zhao; Conghong Fan
Journal:  BMC Med Genet       Date:  2019-06-10       Impact factor: 2.103

6.  Long noncoding RNA PART1 promotes progression of non-small cell lung cancer cells via JAK-STAT signaling pathway.

Authors:  Dengyan Zhu; Yang Yu; Wei Wang; Kai Wu; Donglei Liu; Yang Yang; Chunyang Zhang; Yu Qi; Song Zhao
Journal:  Cancer Med       Date:  2019-08-22       Impact factor: 4.452

7.  Downregulated Long Noncoding RNA PART1 Inhibits Proliferation and Promotes Apoptosis in Bladder Cancer.

Authors:  Xin Hu; Hefei Feng; Huaxing Huang; Wei Gu; Qiuyu Fang; Yi Xie; Chao Qin; Xiaowen Hu
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

8.  Inhibition of lncRNA PART1 Chemosensitizes Wild Type but Not KRAS Mutant NSCLC Cells.

Authors:  Shu-Chen Chen; Yu-Zhu Diao; Zi-Han Zhao; Xiao-Ling Li
Journal:  Cancer Manag Res       Date:  2020-06-10       Impact factor: 3.989

9.  LncRNA PART1 Promotes Proliferation and Migration, Is Associated with Cancer Stem Cells, and Alters the miRNA Landscape in Triple-Negative Breast Cancer.

Authors:  Brianne M Cruickshank; Marie-Claire D Wasson; Justin M Brown; Wasundara Fernando; Jaganathan Venkatesh; Olivia L Walker; Fiorella Morales-Quintanilla; Margaret L Dahn; Dejan Vidovic; Cheryl A Dean; Carter VanIderstine; Graham Dellaire; Paola Marcato
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

10.  Exosome-mediated transfer of lncRNA PART1 induces gefitinib resistance in esophageal squamous cell carcinoma via functioning as a competing endogenous RNA.

Authors:  Min Kang; Meiping Ren; Yan Li; Yuqiong Fu; Minmin Deng; Changping Li
Journal:  J Exp Clin Cancer Res       Date:  2018-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.